Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Evofem Biosciences Inc
EVFM | US
0.01
USD0.00
1.12%
EVFM | US
About Evofem Biosciences Inc
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
09/03/2026
Close
0.01
Open
0.01
High
0.01
Low
0.01
Evofem Biosciences Inc. a biopharmaceutical company develops and commercializes various products to address unmet needs in women's sexual and reproductive health. Its commercial product is Phexxi a vaginal gel for the prevention of pregnancy. The company is also involved in the development of EVO100 for the prevention of chlamydia and gonorrhea in Women; and EVO200 for the prevention of recurrent bacterial vaginosis. Evofem Biosciences Inc. is headquartered in San Diego California.
View LessEVFM | US
Risk
5.8
Sharpe
0.06
Luna's Score
43/100
Recommendation
Sell
Luna says (EVFM | US)
What's Working
Strong Revenue Growth (> 10%)
What's not Working
High 6-Month Volatility (>65%)
Microcap (<300M USD)
Low negative Beta, possible Low Liquidity (< -0.4)
Rich in Valuation (Price to Book > 8)
Weak Operating Margin (< 10%)
Weak Sharpe Ratio (< 0.3)
Volatility Signals
Bearish: Increased Volatility (6-month > 1-month volatility)
Risk Meter
10 days
7.9%1 month
5.8%3 months
99.5%6 months
152.0%Returns
Fundamental Ratios
PE
0.00
Fwd. PE
-
Price to book
8.37
Debt to equity
-
Debt to assets
-
Ent. to EBITDA
-0.74
Ent. to rev.
2.77
PEG
-
Other Fundamentals
EBITDA
-11.09M
MarketCap
902.96K
MarketCap(USD)
902.96K
Div. yield
-
Op. margin
-33.39
Erngs. growth
-
Rev. growth
69.20
Ret. on equity
-387.27
Short ratio
0.19
Short perc.
11.01
Market Sentiment (SMA and Price signals)
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
SMAs: Stock Price Trends
Range10D
0.00
Range1M
0.00
Range3M
0.01
Volumes: Market Activity
Rel. volume
0.53
Price X volume
575.10
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -0.74 | 0.53 | Cheaper |
| Ent. to Revenue | 2.77 | 3,967.00 | Cheaper |
| PE Ratio | 0.00 | 41.03 | Cheaper |
| Price to Book | 8.37 | 15.55 | Cheaper |
| Dividend Yield | - | 2.20 | - |
| Std. Deviation (3M) | 99.52 | 72.80 | Riskier |
| Debt to Equity | - | -1.23 | - |
| Debt to Assets | - | 0.25 | - |
| Market Cap | 902.96K | 3.66B | Emerging |
